• pseudomyxoma peritonei (PMP) • liver tumor (primary cancer or colorectal liver metastases) • pancreatic cancer • bile duct cancer • colorectal cancer
Conditions
Interventions
None
Sponsors
This work is supported by a grant from the UMCG Cancer Research Foundation (Institutional Foundation for Cancer Research and Development). The study protocol has not undergone any peer-review by this funding body, nor will they play a role in the analysis and interpretation of the data.
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a patient must meet all of the following inclusion criteria: • Age = 18 years; • Able to read and understand the Dutch language; • Diagnosed or the suspicion of a liver tumor (primary cancer or colorectal liver metastases), pancreatic malignancy, bile duct malignancy, colon tumor, rectum tumor, or pseudomyxoma peritonei; • Scheduled to undergo elective open major abdominal surgery at UMCG, consisting of the following surgical procedures: o cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy (CRS with HIPEC); o (sub)total pelvic exenteration; o pylorus preserving pancreaticoduodenectomy (PPPD); o whipple procedure (classic pancreaticoduodenectomy); o (sub)total pancreatectomy; or o major liver resection defined as =3 liver segments. • Presence of a preoperative computed tomography (CT) of the abdomen to determine sarcopenia preoperatively; • Has given informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: A potential eligible patient who meets any of the following exclusion criteria will be excluded from participation in this study: • Scheduled to undergo emergency resection; • Scheduled to undergo laparoscopic surgery; • Scheduled to undergo minor liver resections (defined as <3 liver segments); • Inability to co-operate and give informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of this study is the proportion of patients who have clinically relevant SRML, defined as =5% muscle loss within one week after surgery measured by bedside ultrasound measurements. | — |
Secondary
| Measure | Time frame |
|---|---|
| For the different secondary endpoints patients will be divided in two subgroups: patients with and without clinically relevant SRML. Our secondary endpoints will be the difference within both groups regarding: • Amount of loss of muscle mass per day after surgery; • Total amount of loss of muscle mass during hospital stay; • Specific patterns of muscle loss after surgery; • Amount of decrease in muscle strength per day after surgery; • Total decrease in muscle strength during hospital stay; • Specific patterns of decrease in muscle strength after surgery; • Possible risk factors for clinically relevant SRML: o Insufficient physical activity postoperatively; o Insufficient protein intake postoperatively; o Sarcopenia preoperatively; o Age = 65 years; o Diabetes preoperatively; o Major postoperative complications; • Correlation of urinary Creatinine Excretion Rate (CER); • Correlation of Patient-Generated Subjective Global Assessment (PGSGA); • Unplanned readmissions within 30 days after discharge; • QoL and fatigue three and six months after surgery. | — |
Contacts
Public ContactJudith Hentzen
University Medical Center Groningen (UMCG)
Outcome results
None listed